BrainsWay Ltd.
BWAYBrainsWay Ltd. in brief
BrainsWay Ltd. is a listed company in the Healthcare sector, based in Israel. It was founded in 2003. Its market value was $602 M on 1 August 2026, which makes it the 11,774th largest listed company in the world and the 128th largest in Israel on this site. In the year to December 2024 it had sales of $41 M and a net profit of $3 M, about 7 cents of profit for every dollar of sales. Hadar Levy is its chief executive. Its shares trade under the symbol BWAY (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About BrainsWay Ltd.
BrainsWay Ltd. (Hebrew: בריינסוויי) is an international company that is engaged in the development of a medical device that uses H-coil for deep transcranial magnetic stimulation (Deep TMS) as a non-invasive treatment for depression, OCD, and smoking addiction. The company was founded in 2003 and has offices in the US and Jerusalem.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
BrainsWay Ltd. timeline
- 2003
- 🏁· approximateFounded
- 2011
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2019
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 17 April 2019; shares registered for exchange trading on 11 April 2019.
Events of BrainsWay Ltd. from Wikidata and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in Israel: #193 (Jan 2020) · #244 (Jan 2021) · #268 (Jan 2022) · #332 (Dec 2022) · #354 (Jul 2023) · #232 (Jan 2024) · #12 (Mar 2026) · #129 (Aug 2026)
Key ratios
- P/E ratio (TTM)
- 206.0×
- Price / sales (TTM)
- 14.7×
- Price / book
- 9.7×
- Free cash flow yield
- -0.2%
- Net margin (TTM)
- 7.1%
- Operating margin
- 3.4%
- Return on equity
- 4.7%
- Liabilities / assets
- 33.9%
- Net debt
- $-7M
- Revenue growth
- +29.1%
- R&D / revenue
- 17.5%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2024 | $41M | +29.1% | $1M | $3M | 7.1% |
| Dec 2023 | $32M | +16.9% | $-5M | $-4M | -13.2% |
| Dec 2022 | $27M | -8.4% | $-13M | $-13M | -49.1% |
| Dec 2021 | $30M | +34.5% | $-5M | $-6M | -21.8% |
| Dec 2020 | $22M | -4.5% | $-5M | $-5M | -24.4% |
| Dec 2019 | $23M | +40.9% | $-8M | $-10M | -44.7% |
| Dec 2018 | $16M | +47.2% | $-5M | $-6M | -39.5% |
| Dec 2017 | $11M | — | $-7M | $-7M | -63.3% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2024 | $10M | — | — | $0.05 | — |
| Dec 2023 | $1M | — | — | $-0.13 | — |
| Dec 2022 | $-10M | — | — | $-0.40 | — |
| Dec 2021 | $1M | $2M | $-1M | $-0.21 | — |
| Dec 2020 | $-1M | $2M | $-4M | — | — |
| Dec 2019 | $-7M | $3M | $-11M | — | — |
| Dec 2018 | $-4M | $2M | $-6M | — | — |
| Dec 2017 | $-3M | $1M | $-4M | — | — |
SEC filings
- Nov 10, 20266-KReport of foreign issuer
- Nov 10, 20266-KReport of foreign issuer
- Nov 2, 20266-KReport of foreign issuer
- Oct 26, 20266-KReport of foreign issuer
- Oct 21, 20266-KReport of foreign issuer
- Oct 19, 20266-KReport of foreign issuer
- Oct 13, 20266-KReport of foreign issuer
- Sep 29, 20266-KReport of foreign issuer
- Sep 8, 20266-KReport of foreign issuer
- Aug 27, 20266-KReport of foreign issuer
- Aug 12, 20266-KReport of foreign issuer
- Aug 12, 20266-KReport of foreign issuer
Official filings of BrainsWay Ltd. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $41 M
- Operating income
- $1 M
- Net income
- $3 M
For year ending December-2024 · source: SEC filing
Balance sheet
- Total assets
- $94 M
- Total liabilities
- $32 M
- Total equity
- $62 M
As of December-2024
Top 65 institutional investors in BrainsWay Ltd.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Valor Management LLC | 5,314,950 | 0 (0.00%) | 13.45% | $70 M | Nov 16, 2026 |
| 2 | Masters Capital Management LLC | 1,246,099 | -253,901 (-16.93%) | 3.15% | $16 M | Nov 16, 2026 |
| 3 | Acadian Asset Management LLC | 769,366 | -38,565 (-4.77%) | 1.95% | $10 M | Nov 9, 2026 |
| 4 | Essex Investment Management Co LLC | 574,818 | -17,788 (-3.00%) | 1.46% | $8 M | Oct 19, 2026 |
| 5 | Renaissance Technologies LLC | 445,520 | -30,400 (-6.39%) | 1.13% | $6 M | Nov 12, 2026 |
| 6 | Cresset Asset Management, LLC | 314,924 | 0 (0.00%) | 0.80% | $4 M | Nov 16, 2026 |
| 7 | HWG Holdings LP | 253,050 | New | 0.64% | $3 M | Oct 8, 2026 |
| 8 | Morgan Stanley | 250,713 | +61,745 (+32.67%) | 0.63% | $3 M | Nov 13, 2026 |
| 9 | Y.D. More Investments Ltd | 224,382 | -13,051 (-5.50%) | 0.57% | $3 M | Nov 2, 2026 |
| 10 | Eagle Global Advisors LLC | 182,606 | 0 (0.00%) | 0.46% | $2 M | Nov 2, 2026 |
| 11 | Legato Capital Management LLC | 176,569 | -21,066 (-10.66%) | 0.45% | $2 M | Nov 10, 2026 |
| 12 | ARK Investment Management LLC | 146,850 | +4,350 (+3.05%) | 0.37% | $2 M | Nov 13, 2026 |
| 13 | Jpmorgan Chase & Co | 127,019 | +30,212 (+31.21%) | 0.32% | $2 M | Nov 12, 2026 |
| 14 | SEI Investments Co | 119,717 | 0 (0.00%) | 0.30% | $2 M | Nov 10, 2026 |
| 15 | Walleye Capital LLC | 106,834 | New | 0.27% | $1 M | Nov 13, 2026 |
| 16 | Two Sigma Investments, LP | 105,859 | +6,314 (+6.34%) | 0.27% | $1 M | Nov 16, 2026 |
| 17 | Royce & Associates LP | 97,033 | 0 (0.00%) | 0.25% | $1 M | Nov 9, 2026 |
| 18 | Huntleigh Advisors, Inc. | 91,072 | +3,766 (+4.31%) | 0.23% | $1 M | Nov 3, 2026 |
| 19 | Tidal Investments LLC | 87,375 | -1,873 (-2.10%) | 0.22% | $1 M | Nov 13, 2026 |
| 20 | Bank Of America Corp /de/ | 61,287 | New | 0.16% | $1 M | Nov 16, 2026 |
| 21 | Wells Fargo & Company/mn | 58,980 | +3,351 (+6.02%) | 0.15% | $1 M | Nov 16, 2026 |
| 22 | Qube Research & Technologies Ltd | 51,485 | New | 0.13% | $1 M | Nov 13, 2026 |
| 23 | Sigma Planning Corp | 50,635 | -49,800 (-49.58%) | 0.13% | $1 M | Oct 23, 2026 |
| 24 | Voleon Capital Management LP | 44,439 | +19,628 (+79.11%) | 0.11% | $1 M | Nov 16, 2026 |
| 25 | Bullseye Asset Management LLC | 41,482 | 0 (0.00%) | 0.10% | $1 M | Nov 13, 2026 |
Show all 65: investors 26 to 65
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Man Group plc | 40,311 | +12,837 (+46.72%) | 0.10% | $1 M | Nov 16, 2026 |
| 27 | UBS Group AG | 35,074 | -66,003 (-65.30%) | 0.09% | $0 M | Nov 10, 2026 |
| 28 | Goldman Sachs Group Inc | 33,067 | -59,024 (-64.09%) | 0.08% | $0 M | Nov 16, 2026 |
| 29 | Rhumbline Advisers | 32,275 | -5,234 (-13.95%) | 0.08% | $0 M | Nov 10, 2026 |
| 30 | State of Wyoming | 32,015 | -6,730 (-17.37%) | 0.08% | $0 M | Oct 28, 2026 |
| 31 | Quadrature Capital Ltd | 29,152 | -33,942 (-53.80%) | 0.07% | $0 M | Nov 13, 2026 |
| 32 | Stifel Financial Corp | 22,000 | New | 0.06% | $0 M | Nov 12, 2026 |
| 33 | BNP Paribas Financial Markets | 21,576 | New | 0.05% | $0 M | Nov 12, 2026 |
| 34 | Citadel Advisors LLC | 21,196 | -26,323 (-55.39%) | 0.05% | $0 M | Nov 16, 2026 |
| 35 | LPL Financial LLC | 18,800 | New | 0.05% | $0 M | Nov 6, 2026 |
| 36 | Commonwealth Of Pennsylvania Public School Empls Retrmt Sys | 17,470 | 0 (0.00%) | 0.04% | $0 M | Nov 3, 2026 |
| 37 | Crossmark Global Holdings, Inc. | 14,950 | -10,401 (-41.03%) | 0.04% | $0 M | Oct 21, 2026 |
| 38 | Royal Bank Of Canada | 14,541 | -399 (-2.67%) | 0.04% | $0 M | Nov 16, 2026 |
| 39 | Geode Capital Management, LLC | 13,705 | 0 (0.00%) | 0.03% | $0 M | Nov 6, 2026 |
| 40 | HRT Financial LP | 13,331 | New | 0.03% | $0 M | Nov 13, 2026 |
| 41 | Calamos Advisors LLC | 10,255 | New | 0.03% | $0 M | Nov 2, 2026 |
| 42 | State of Tennessee, Department of Treasury | 8,812 | 0 (0.00%) | 0.02% | $0 M | Nov 16, 2026 |
| 43 | BlackRock, Inc. | 5,948 | +4,264 (+253.21%) | 0.02% | $0 M | Nov 13, 2026 |
| 44 | Osaic Holdings, Inc. | 4,569 | +1 (+0.02%) | 0.01% | $0 M | Nov 12, 2026 |
| 45 | GAMMA Investing LLC | 3,634 | 0 (0.00%) | 0.01% | $0 M | Oct 8, 2026 |
| 46 | Fifth Third Bancorp | 2,466 | New | 0.01% | $0 M | Nov 5, 2026 |
| 47 | Montag A & Associates Inc | 2,459 | New | 0.01% | $0 M | Oct 29, 2026 |
| 48 | NewEdge Advisors, LLC | 1,801 | -17,029 (-90.44%) | 0.00% | $0 M | Nov 13, 2026 |
| 49 | Citigroup Inc | 1,717 | +1,714 (+57133.33%) | 0.00% | $0 M | Nov 4, 2026 |
| 50 | TD Waterhouse Canada Inc. | 1,430 | 0 (0.00%) | 0.00% | $0 M | Oct 16, 2026 |
| 51 | Barclays PLC | 1,352 | -83 (-5.78%) | 0.00% | $0 M | Nov 6, 2026 |
| 52 | Lanark Financial, Inc. | 1,100 | 0 (0.00%) | 0.00% | $0 M | Oct 26, 2026 |
| 53 | Simplex Trading, LLC | 461 | New | 0.00% | $0 M | Nov 4, 2026 |
| 54 | Russell Investments Group, Ltd. | 390 | 0 (0.00%) | 0.00% | $0 M | Nov 6, 2026 |
| 55 | Nisa Investment Advisors, LLC | 361 | +26 (+7.76%) | 0.00% | $0 M | Oct 20, 2026 |
| 56 | Farmers & Merchants Investments Inc | 300 | New | 0.00% | $0 M | Oct 22, 2026 |
| 57 | Rothwell Investment Advisors, LLC | 300 | — | 0.00% | $0 M | Nov 6, 2026 |
| 58 | Jones Financial Companies Lllp | 185 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 59 | Steigerwald, Gordon & Koch Inc. | 120 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 60 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 104 | New | 0.00% | $0 M | Nov 16, 2026 |
| 61 | Physician Wealth Advisors, Inc. | 35 | New | 0.00% | $0 M | Oct 20, 2026 |
| 62 | Tower Research Capital LLC (TRC) | 17 | New | 0.00% | $0 M | Nov 16, 2026 |
| 63 | Dogwood Wealth Management LLC | 14 | New | 0.00% | $0 M | Nov 9, 2026 |
| 64 | SBI Securities Co., Ltd. | 10 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 65 | Pinnacle Wealth Planning Services, Inc. | 1 | New | 0.00% | $0 M | Oct 27, 2026 |
Mutual funds holding BrainsWay Ltd.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Timothy Plan Israel Common Values FundTimothy Partners, Ltd. | 182,606 | $3 M | 0.46% | 1.4% | +5.8% | Jun 30, 2026 |
| 🇺🇸 ARK Israel Innovative Technology ETFARK Investment Management LLC | 146,850 | $2 M | 0.37% | 1.6% | +3.1% | Jul 31, 2026 |
| 🇺🇸 1290 Essex Small Cap Growth FundEquitable Investment Management, LLC | 138,592 | $2 M | 0.35% | 1.8% | no change | Jul 31, 2026 |
| 🇺🇸 Royce Smaller-Companies Growth FundRoyce & Associates, LP | 97,000 | $2 M | 0.25% | 0.63% | no change | Jun 30, 2026 |
| 🇺🇸 Amplify BlueStar Israel Technology ETFAmplify ETF Trust | 74,453 | $1 M | 0.19% | 0.96% | new | Jun 30, 2026 |
| 🇺🇸 Old Westbury Small & Mid Cap Strategies FundBessemer Investment Management LLC | 50,627 | $1 M | 0.13% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Steward Values Enhanced International FundCrossmark Global Investments | 25,351 | $0 M | 0.06% | 0.11% | no change | Jul 31, 2026 |
| 🇺🇸 ActivePassive International Equity ETFTrust for Professional Managers | 19,005 | $0 M | 0.05% | 0.03% | +14% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 13,705 | $0 M | 0.03% | <0.01% | +173% | May 31, 2026 |
| 🇺🇸 Voya Multi-Manager International Small Cap FundVoya Investments, LLC | 9,834 | $0 M | 0.02% | 0.03% | no change | Jul 31, 2026 |
| 🇺🇸 iShares International Small-Cap Equity Factor ETFBlackRock Fund Advisors | 8,610 | $0 M | 0.02% | 0.02% | +2.1% | Jul 31, 2026 |
| 🇺🇸 SIT International Equity FundSEI INVESTMENTS MANAGEMENT CORPORATION | 6,021 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Siit World Equity Ex-Us FundSEI INVESTMENTS MANAGEMENT CORPORATION | 2,950 | $0 M | <0.01% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 800 | $0 M | <0.01% | <0.01% | −11% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 14 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at BrainsWay Ltd.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
Too few open-market trades to chart.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Gilad MoiseyevChief Technology Officer | Sell | -5,000 | — | —local | 53,098 | Form 4 |
| filed | Yiftach RothChief Scientist | Sell | -1,000 | — | —local | 1.07 M | Form 4 |
| filed | Yiftach RothChief Scientist | Sell | -2,000 | — | —local | 1.07 M | Form 4 |
| filed | Yiftach RothChief Scientist | Sell | -2,000 | — | —local | 1.08 M | Form 4 |
| filed | Yiftach RothChief Scientist | Sell | -2,000 | — | —local | 1.08 M | Form 4 |
| filed | Mitrany Rayten Michal EtyDirector | Sell | -7,980 | — | —local | 12,500 | Form 4 |
| filed | Gilad MoiseyevChief Technology Officer | Option exercise | +7,500 | — | —local | 60,000 | Form 4 |
| filed | Gilad MoiseyevChief Technology Officer | Shares withheld for tax | -1,902 | — | —local | 58,098 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars
Markets and events: BrainsWay Ltd.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Fails to deliver
- : 100 shares at $11.46
- : 386 shares at $14.27
- : 229 shares at $14.19
- : 230 shares at $14.97
- : 56 shares at $16.32
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
BrainsWay Ltd. scorecard#
Passes 8 of the 12 checks that could be worked out: strongest in growth (5 of 6), weakest in profitability (3 of 5). Fiscal year 2024; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth5 of 6
- ✓Revenue grew in the newest year29.1%Revenue up 29.1% in fiscal 2024.
- ✓Revenue up more than 5% a year over three years11.4%11.4% a year over the three years to fiscal 2024.
- ✓Faster growth over three years than its peers' median11.4%11.4% a year against Healthcare's median of 8.5% (549 companies).
- ✓Earnings per share grew in the newest year0.05 vs -0.13Diluted EPS 0.05 in fiscal 2024 against -0.13 the year before (report's currency).
- ✓Net income higher than five years earlier$3 M$3 M in fiscal 2024 against -$10 M in 2019.
- ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2024.
Profitability3 of 5
- ✓Profitable in the newest year$3 MNet income $3 M in fiscal 2024.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2024.
- ✓Operating margin above its peers' median3.4%3.4% against Healthcare's median of -7.7% (674 companies).
- ✗Return on equity above 15%5.6%5.6% in fiscal 2024.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier3.4%3.4% in fiscal 2024 against -16.9% in 2021.
Financial health0 of 1
- –Short-term assets cover short-term liabilitiesCurrent assets and liabilities are not on file.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years2 of 3Positive in 2 of the three years to fiscal 2024.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2024#
Worked out from BrainsWay Ltd.'s statements, beside the median of Healthcare.
| Ratio | Trend | 2024 | Median of peers |
|---|---|---|---|
| Operating margin | 3.4% | -7.7% | |
| Net margin | 7.1% | -8.1% | |
| Return on equity | 5.6% | -36.9% | |
| Revenue growth, 3 years a year | 11.4% | 8.5% | |
| Revenue growth | 29.1% | 10.2% |
5of 7on the Piotroski tests of financial strength
BrainsWay Ltd.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 41+29.0%100% | 32+17.0%100% | 27−8.4%100% | 30+34.5%100% | 22−4.5%100% | 23+40.9%100% | 16+47.1%100% | 11—100% | |
| Cost of revenue | 10+25.6%25.4% | 8.3+16.5%26.1% | 7.1+8.0%26.2% | 6.6+30.5%22.3% | 5.1−1.4%22.9% | 5.1+42.9%22.2% | 3.6+38.3%21.9% | 2.6—23.3% | |
| Gross profit | 31+30.3%74.6% | 23+17.1%73.9% | 20−13.1%73.8% | 23+35.6%77.7% | 17−5.4%77.1% | 18+40.3%77.8% | 13+49.8%78.1% | 8.6—76.7% | |
| Research and development | 7.2+7.9%17.5% | 6.7−13.2%21.0% | 7.7+20.1%28.3% | 6.4+9.8%21.6% | 5.8−26.1%26.4% | 7.9+27.9%34.1% | 6.2+15.2%37.5% | 5.3—47.9% | |
| Selling and marketing | 16−1.5%39.5% | 16−9.6%51.8% | 18+14.6%67.0% | 16+40.7%53.5% | 11−15.0%51.2% | 13+59.0%57.4% | 8.3+31.8%50.9% | 6.3—56.8% | |
| Total costs and expenses | 29+2.7%71.2% | 28−13.1%89.5% | 33+16.7%120% | 28+28.5%94.6% | 22−17.5%99.0% | 26+47.6%114% | 18+18.2%109% | 15—136% | |
| Operating income | 1.4—3.4% | −5.0—−15.6% | −13—−46.7% | −5.0—−16.9% | −4.8—−21.9% | −8.5—−36.7% | −5.1—−31.2% | −6.6—−59.3% | |
| Interest and finance income | 3.6+65.1%8.7% | 2.2+94.4%6.8% | 1.1+338%4.1% | 0.3—0.9% | — | — | — | — | |
| Interest expense and finance costs | 1.5+30.9%3.7% | 1.2r−1.2−21.1%3.6% | 1.5r0.4—5.4% | −1.7r1.4−625%−5.6% | 0.3−77.7%1.4% | 1.4+23.7%6.2% | 1.2+322%7.1% | 0.3—2.5% | |
| Income before tax | 3.5—8.4% | −3.9—−12.4% | −13—−48.0% | −6.4—−21.6% | −5.1—−23.3% | −9.9—−42.9% | −6.3—−38.2% | −6.9—−61.8% | |
| Income tax | 0.5+114%1.3% | 0.3−20.3%0.8% | 0.3+633%1.2% | 0.0−81.9%0.1% | 0.2−43.8%1.1% | 0.4+102%1.8% | 0.2+23.7%1.3% | 0.2—1.5% | |
| Net income including minority interests | 2.9—7.1% | −4.2—−13.2% | −13—−49.1% | −6.5—−21.8% | −5.4—−24.4% | −10—−44.7% | −6.5—−39.5% | −7.1—−63.3% | |
| Earnings per share, basic | 0.09—— | -0.13—— | -0.40—— | -0.21—— | — | — | — | — | |
| Earnings per share, diluted | 0.05—— | -0.13—— | -0.40—— | -0.21—— | — | — | — | — | |
| Shares, weighted average (basic) | 34+2.5%— | 33+0.5%— | 33+5.9%— | 31+38.8%— | 22+9.5%— | 21+23.2%— | 17+12.7%— | 15—— | |
| Balance sheet | |||||||||
| Cash and cash equivalents | 69+559%73.5% | 11−77.9%16.7% | 48+181%73.8% | 17−0.2%22.3% | 17−21.7%49.9% | 22+142%56.0% | 9.0−38.2%38.0% | 15—— | |
| Inventory | 4.4+19.1%4.7% | 3.7−3.1%5.9% | 3.8—6.0% | — | — | — | — | — | |
| Other current assets | 1.0−39.7%1.1% | 1.7+10.0%2.7% | 1.6−11.9%2.4% | 1.8+15.1%2.3% | 1.5—4.5% | — | — | — | |
| Current assets | 80+43.6%84.5% | 55−4.5%88.1% | 58−11.2%90.1% | 65+169%86.4% | 24−15.7%71.4% | 29+114%74.4% | 13—57.1% | — | |
| Property, plant and equipment | — | — | — | — | 4.4+2.4%12.8% | 4.2+44.7%11.0% | 2.9—12.4% | — | |
| Right-of-use (leased) assets | 5.5+1192%5.9% | 0.4—0.7% | — | — | — | — | — | — | |
| Non-current assets | 15+95.1%15.5% | 7.5+17.5%11.9% | 6.4−37.9%9.9% | 10+5.9%13.6% | 9.7−2.0%28.6% | 9.9−2.1%25.6% | 10—42.9% | — | |
| Total assets | 94+49.8%100% | 63−2.3%100% | 64−14.9%100% | 76+123%100% | 34−12.2%100% | 39+64.1%100% | 24—100% | — | |
| Accounts payable | 5.9+12.7%6.3% | 5.3r5.5+17.1%8.4% | 4.5−6.3%7.0% | 4.8+27.1%6.3% | 3.8+11.5%11.1% | 3.4−2.3%8.7% | 3.5—14.7% | — | |
| Current liabilities | 15+57.2%16.3% | 9.8+19.9%15.5% | 8.1−10.2%12.6% | 9.1+33.3%12.0% | 6.8+1.2%20.0% | 6.7−19.4%17.3% | 8.3—35.3% | — | |
| Long-term debt | — | — | — | — | — | — | 2.1—8.8% | — | |
| Lease liabilities (non-current) | 4.8+1908%5.1% | 0.2−5.9%0.4% | 0.30.0%0.4% | 0.3+4.5%0.3% | 0.2−63.3%0.7% | 0.7—1.7% | — | — | |
| Non-current liabilities | 17+43.2%17.7% | 12+6.3%18.5% | 11+17.1%17.0% | 9.3+23.3%12.3% | 7.6−2.8%22.3% | 7.8−6.2%20.1% | 8.3—35.2% | — | |
| Retained earnings | −98—−104% | −101—−161% | −97—−151% | −84—−111% | −77—−227% | −72—−186% | −62—−261% | — | |
| Total equity | 62+49.9%66.1% | 42−8.4%66.0% | 45−20.8%70.4% | 57+192%75.7% | 20−18.9%57.7% | 24+248%62.5% | 7.0−45.4%29.5% | 13—— | |
| Total liabilities and equity | 94+49.8%100% | 63−2.3%100% | 64−14.9%100% | 76+123%100% | 34−12.2%100% | 39+64.1%100% | 24—100% | — | |
| Shares outstanding | 38+13.2%— | 33+0.6%— | 33+0.4%— | 33+47.9%— | 22+0.1%— | 22+33.6%— | 17—— | — | |
| Cash-flow statement | |||||||||
| Depreciation and amortization | 0.7+82.3%1.6% | 0.4−35.1%1.1% | 0.6−0.4%2.1% | 0.6+27.9%1.9% | 0.4r1.5−20.4%2.0% | 0.6r1.7+18.8%2.4% | 0.5+17.5%2.8% | 0.4—3.5% | |
| Share-based compensation | 1.4+278%3.5% | 0.4−74.2%1.2% | 1.5−22.1%5.4% | 1.9+137%6.4% | 0.8−36.7%3.6% | 1.3+77.9%5.5% | 0.7−30.9%4.3% | 1.0—9.2% | |
| Cash from operating activities | 10+702%25.1% | 1.3—4.0% | −9.8−1204%−35.9% | 0.9—3.0% | −1.4—−6.5% | −7.2—−31.4% | −3.8—−23.0% | −3.5—−31.1% | |
| Capital expenditure | — | — | — | −2.2—−7.5% | −2.5—−11.2% | −3.3—−14.3% | −2.0—−12.0% | −1.0—−8.8% | |
| Cash from investing activities | 30—73.9% | −37−189%−118% | 42—155% | −42—−142% | −2.5—−11.2% | −2.4—−10.6% | −1.1—−6.9% | −2.5—−22.0% | |
| Debt issued | — | — | — | — | — | −3.0—−13.0% | — | 2.7—24.2% | |
| Shares issued | — | — | −0.1−100%−0.2% | 42—142% | — | 26—114% | — | 8.4—75.8% | |
| Cash from financing activities | 18—44.5% | −1.0—−3.2% | −1.5−104%−5.7% | 42—140% | −1.0−105%−4.7% | 22—97.3% | −0.3−102%−1.6% | 11—99.7% | |
| Exchange-rate effect on cash | −0.0−152%−0.1% | 0.1—0.3% | −0.2—−0.7% | −0.2−203%−0.8% | 0.2—1.0% | −0.1—−0.3% | −0.4−353%−2.2% | 0.1—1.3% | |
| Change in cash | 59—143% | −37−221%−117% | 31—113% | −0.0—−0.1% | −4.7−137%−21.4% | 13—55.0% | −5.5−204%−33.8% | 5.3—47.9% | |
| Report | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Dec 31, 2024. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where BrainsWay Ltd. operates: 2 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.
| Country | Presence | Revenue there |
|---|---|---|
| 🇮🇱 Israel | Headquarters1 office | — |
| 🇵🇸 Palestine | 1 office | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Sep 2024 | $20 M | Private placement after listing | $10 to $50 million | 1 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Discuss BrainsWay Ltd.#
1 automatic updates and 0 member comments. Sign in to comment and react.
- Mutual funds: 14 funds hold $12 millionautomatic update · Jul 31, 2026
14 mutual funds in 1 country hold shares of BrainsWay Ltd. worth $12 million, about 2.0% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 8 funds added shares and 1 sold; on balance they bought $2 million. Share splits are not counted as trading.
How BrainsWay Ltd. compares in Healthcare
- Market cap$602 M · higher than 48% of 2,013
- Revenue$41 M · higher than 32% of 1,795
- Net margin7.1% · higher than 62% of 1,485
- Revenue growth29.1% · higher than 76% of 1,003
- P/E ratio206.0× · lower than 4% of 605
- Price / sales14.7× · lower than 16% of 1,071
- Price / book9.7× · lower than 14% of 1,245
- FCF yield-0.2% · higher than 66% of 835
Peer comparison · Healthcare
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| BrainsWay Ltd.🇮🇱 | $602 M | 206.0× | 7.1% | +29.1% |
| Eli Lilly and Company🇺🇸 | $1.20 T | 43.4× | 31.9% | +44.7% |
| Johnson & Johnson🇺🇸 | $652.5 B | 40.5× | 16.2% | +6.0% |
| AbbVie Inc.🇺🇸 | $514.0 B | 49.7× | 15.7% | +8.6% |
| Roche Holding AG🇨🇭 | $370.3 B | 29.1× | 19.0% | — |
| UnitedHealth Group Incorporated🇺🇸 | $367.7 B | 23.1× | 3.5% | +11.8% |
| Merck & Co., Inc.🇺🇸 | $359.8 B | 146.7× | 3.6% | +1.3% |
| Novartis AG🇨🇭 | $286.8 B | 20.5× | 24.7% | — |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2024
- Balance sheet:
- As of December-2024
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, Wikipedia, Wikidata; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at BrainsWay Ltd.? Verify and update this profile — free
Show BrainsWay Ltd.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.